Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

October 25, 2017

AstraZeneca and Merck Seeking Lynparza Approval in Japan for Certain Breast Cancer Patients

News

AstraZeneca and Merck submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking the approval of Lynparza (olaparib) tablets for the treatment of patients with unresectable or ... Read more

October 20, 2017October 20, 2017

FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose ... Read more

September 22, 2017September 22, 2017

Taselisib-Femara Combo Improves Response in Certain Postmenopausal Women with Early Breast Cancer, Study Shows

News

Adding taselisib to Femara (letrozole) increases the measurable response in certain postmenopausal women with early breast cancer, according to a new study. The benefits were also seen in women whose tumors had ... Read more

September 8, 2017September 8, 2017

LUM Imaging System to Detect Residual Cancer During Surgery to Start Advanced Clinical Trial

News

A possibly pivotal clinical trial using an imaging technology – the LUM Imaging System by Lumicell — to detect residual tumor tissue in breast cancer patients undergoing surgery is in the planning ... Read more

September 7, 2017

Even Small Breast Tumors Can be Aggressive, and Patients Can Benefit from Chemotherapy, Study Shows

News

While many doctors consider small tumors less harmful, new data from the international MINDACT breast cancer study suggests otherwise. In the study, nearly one in four early-stage breast cancer patients with ... Read more

July 18, 2017

Nerlynx Approved by FDA for HER2-positive Breast Cancer Patients to Reduce Risk of Recurrence

News

The U.S. Food and Drug Administration (FDA) approved Puma Biotechnology‘s Nerlynx (neratinib) as an extended adjuvant treatment of early-stage, HER2-positive breast cancer. This means that Nerlynx is the first extended adjuvant therapy for ... Read more

May 5, 2017May 5, 2017

Full Interview with Agendia’s CMO on MammaPrint 70-gene Signature Test

News

Breast Cancer News, in an email exchange, interviewed Dr. William Audeh, chief medical officer of Agendia and a breast medical oncologist with nearly 30 years of clinical practice experience, to know more ... Read more

May 5, 2017May 8, 2017

MammaPrint Genomic Test Helps Early Stage Cancer Patients Safely Avoid Chemo, Agendia’s CMO Says

News

A genomic test, evaluated in several clinical trials and approved for use in the U.S. and Europe, can effectively tell early stage breast cancer patients what is their risk of cancer returning. ... Read more

May 3, 2017

COMET Trial Now Recruiting to Study Active Surveillance in Low-risk DCIS

News

A new breast cancer clinical trial called COMET (NCT02926911) is now enrolling participants to evaluate the risks and benefits of a monitoring approach vs. a full-mode attack with surgery and ... Read more

April 5, 2017April 5, 2017

New Drug Loaded into Nanoparticle Kills Cells in Aggressive Breast Cancer, U.K. Study Shows

News

Researchers in Great Britain have developed a potential new drug to target highly aggressive “triple negative” breast cancer (TNBC) — as well as a biodegradable nanoparticle to deliver it directly into ... Read more